Figure 6(a) shows additionalchanges in the % difference of CD8+ T cell subsets as well as IFN-γ, perforin, and CD27−CD28− subsets burden after LDLT in comparison with the pretransplant immune status atvarious times and the scatterplots showing the relationship between the % E difference and the proportion ofCD8+ effector T cells in a representative of Group II recipient(62-year-old male) undergoing LDLT to treat HCV-related cirrhosis andhepatocellular carcinoma. This evidence concerns the gene PRF1 and carcinoma.